Cargando…

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

Cdk9 is a key elongation factor for RNA transcription and functions by phosphorylating the C-terminal domain of RNA polymerase II. Here we present direct evidence that cdk9 is important for cancer cell survival and describe the characterization of the potent cdk9 inhibitor CDKI-73 in primary human l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walsby, Elisabeth, Pratt, Guy, Shao, Hao, Abbas, Abdullah Y., Fischer, Peter M., Bradshaw, Tracey D., Brennan, Paul, Fegan, Chris, Wang, Shudong, Pepper, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964214/ https://www.ncbi.nlm.nih.gov/pubmed/24495868

Ejemplares similares

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
por: Walsby, Elisabeth, et al.
Publicado: (2012)

Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit nuclear factor-κB activity and synergize with bortezomib and ibrutinib in hematologic cancers
por: Lewis, Thomas, et al.
Publicado: (2020)

Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73
por: Lam, Frankie, et al.
Publicado: (2014)

Targeting CDK9 for treatment of colorectal cancer
por: Rahaman, Muhammed H., et al.
Publicado: (2019)

Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity
por: Hole, Alison J., et al.
Publicado: (2012)

Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities
por: Shao, Hao, et al.
Publicado: (2013)

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition
por: Pepper, C, et al.
Publicado: (2015)

Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells
por: Pepper, C, et al.
Publicado: (2007)

CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems
por: Kouzeli, Ariadni, et al.
Publicado: (2020)

Neurological illness following treatment with fludarabine.
por: Johnson, P. W., et al.
Publicado: (1994)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
por: Costa, Renata Oliveira, et al.
Publicado: (2012)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML
por: Gerlach, Daniel, et al.
Publicado: (2018)

Matrix Metalloproteinase-9 Is Involved in Chronic Lymphocytic Leukemia Cell Response to Fludarabine and Arsenic Trioxide
por: Amigo-Jiménez, Irene, et al.
Publicado: (2014)

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014)

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
por: Pogacar, Ziva, et al.
Publicado: (2022)

Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor
por: Pepper, Chris, et al.
Publicado: (2017)

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents
por: Anshabo, Abel Tesfaye, et al.
Publicado: (2021)

Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
por: Whelan, J. S., et al.
Publicado: (1991)

Fludarabine in the treatment of chronic lymphocytic leukemia: a review
por: Ricci, Francesca, et al.
Publicado: (2009)

Low-grade lymphoma: Beyond fludarabine-single therapy
por: Park, Eunkyung
Publicado: (2011)

Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
por: Janssens, Ann, et al.
Publicado: (2009)

Fludarabine-induced bradycardia in a patient with refractory leukemia
por: Chung-Lo, Woei, et al.
Publicado: (2010)

CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification
por: Reid, Reiss A, et al.
Publicado: (2015)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL
por: Nichols, Eva-Maria, et al.
Publicado: (2015)

Telomere fusions associate with coding sequence and copy number alterations in CLL
por: Escudero, Laura, et al.
Publicado: (2019)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
por: Ferracin, Manuela, et al.
Publicado: (2010)

Telomerase Contributes to Fludarabine Resistance in Primary Human Leukemic Lymphocytes
por: Shawi, May, et al.
Publicado: (2013)

Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
por: Gaur, Tarang, et al.
Publicado: (2023)

Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia
por: Moussay, Etienne, et al.
Publicado: (2010)

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT
por: Bug, Gesine, et al.
Publicado: (2023)

Synergism of ursolic acid derivative US597 with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual-targeting of apoptosis and glycolysis
por: Wang, Jichuang, et al.
Publicado: (2014)

CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
por: He, Lixiazi, et al.
Publicado: (2022)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor
por: Whittaker, Steven R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pnunl2p2nqt1o5n4ggks130sb3